| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
CCCI-01 targets centrosome clustering in cancer cells. Cancer cells often have supernumerary centrosomes and cluster them to form bipolar spindles and avoid mitotic catastrophe. By inhibiting centrosome clustering, CCCI-01 forces cancer cells to form multipolar spindles, leading to mitotic catastrophe and cell death.
|
|---|---|
| ln Vitro |
CCCI-01 is a centrosome cluster inhibitor that has selective effects on cancer cells. It induces apoptosis and has anticancer activity. It can be used in the study of non-cross-resistant anticancer compounds that block centrosome clustering.
|
| ln Vivo |
Specific in vivo activity data for CCCI-01 is not extensively detailed in the available literature. As a research compound, its in vivo effects are primarily studied in the context of centrosome clustering inhibition and its impact on tumor growth. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic properties.
|
| Enzyme Assay |
CCCI-01's activity as a centrosome clustering inhibitor is assessed using in vitro cell-based assays. These assays typically involve treating cancer cells with supernumerary centrosomes with the compound and measuring the percentage of cells with multipolar spindles. The compound's effects on mitotic progression and cell death are assessed.
|
| Cell Assay |
Cellular assays for CCCI-01 involve treating cancer cell lines with the compound and measuring cell proliferation, viability, and mitotic progression. The compound's ability to induce multipolar spindle formation and mitotic catastrophe is assessed by immunofluorescence microscopy. Apoptosis is measured using caspase activation assays or annexin V staining.
|
| Animal Protocol |
In vivo animal model protocols for CCCI-01 would involve its administration to tumor-bearing mice to evaluate its antitumor efficacy. The compound's effects on tumor growth, centrosome clustering in tumor tissues, and survival would be assessed.
|
| ADME/Pharmacokinetics |
CCCI-01 has a molecular weight of 247.21. Specific pharmacokinetic data is not extensively detailed in the available literature. As a small molecule inhibitor, its pharmacokinetic properties would need to be evaluated in preclinical studies.
|
| Toxicity/Toxicokinetics |
The toxicological profile of CCCI-01 has not been extensively characterized. As a research compound, it is intended for research use only and not for human consumption. Standard safety assessments would be required for clinical development.
|
| Additional Infomation |
CCCI-01 (CAS# 215778-97-5) is a research compound used to study centrosome dynamics, mitotic regulation, and chromosomal instability in cancer. It is a centrosome clustering inhibitor with selective effects on cancer cells. It is not approved for clinical use and is supplied as a research chemical.
|
| Molecular Formula |
C11H9N3O4
|
|---|---|
| Molecular Weight |
247.21
|
| Exact Mass |
247.059
|
| Elemental Analysis |
C, 53.44; H, 3.67; N, 17.00; O, 25.89
|
| CAS # |
215778-97-5
|
| PubChem CID |
693996
|
| Appearance |
Solid powder
|
| LogP |
2.426
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
318
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=[N+](C1=CC=C(C(NCC2=CC=CN=C2)=O)O1)[O-]
|
| InChi Key |
OBZHOVWNZIVCCZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H9N3O4/c15-11(9-3-4-10(18-9)14(16)17)13-7-8-2-1-5-12-6-8/h1-6H,7H2,(H,13,15)
|
| Chemical Name |
5-nitro-N-(pyridin-3-ylmethyl)furan-2-carboxamide
|
| Synonyms |
CCCI01; CCCI 01; CCCI-01
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~404.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0451 mL | 20.2257 mL | 40.4514 mL | |
| 5 mM | 0.8090 mL | 4.0451 mL | 8.0903 mL | |
| 10 mM | 0.4045 mL | 2.0226 mL | 4.0451 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
